Authors
Latest:
Developing a Product Launch Strategy for an Orphan DrugCommercializing an orphan drug can be challenging, however, using a framework and a checklist that incorporates the right elements can prove beneficial.
Latest:
Securities Litigation Arising from Alzheimer's Drug TreatmentsThe legal challenges surrounding Biogen’s Aduhelm and Cassava Sciences’ simufilam underscore the ongoing difficulties in Alzheimer's drug development, leading to securities litigation over allegedly misleading statements about trial results and commercialization efforts.
Latest:
How AI is Revamping the Product LaunchNew technology is allowing teams to analyze data at faster rates and make decisions much sooner than they previously could.
Latest:
Rx Power Struggle: How Pharma can Flip the PBM ScriptThe industry holds the key to true change to the drug access landscape.
Latest:
Validating COAs: Key Steps for Accurate and Reliable Clinical Trial DataWith the increasing adoption of COAs, the importance of standardization across training, collection, and implementation to ensure high quality and consistent data collection has become apparent in recent decades.
Latest:
How Technology Can be Used to Improve AdherenceComprehensive dosage monitoring of topical treatments for mild to moderate psoriasis.
Latest:
Turning COVID-19 Era Regulatory Efficiencies into Long-term Business Growth and InnovationCOVID-19 pandemic sets new standards for life sciences industry.
Latest:
Understanding Healthcare Access Barriers: Industry Trends and the Patient Assistance ApproachWebinar Date/Time: Thu, Mar 28, 2024 2:00 PM EDT
Latest:
The Interplay Between COVID-19 Pandemic and NCD EpidemicAmid attention on coronavirus, efforts to address the burden of non-communicable diseases are at a critical juncture.
Latest:
Combating the Opioid Crisis With Long-Acting InjectablesSubstance use disorder is a complex condition that demands innovative solutions, one of which that has shown promise is the use of long-acting injectables.
Latest:
Investing for Success: Finding the Right Launch BalanceChallenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
Latest:
Clues on Equity Engagement LevelsA survey of 18 biopharmas, measuring their scope and implementation across key health equity dimensions and activities, uncovers useful context as companies seek better alignment of these goals with overall strategy.
Latest:
Data Intermediaries/Software Can Speed the Usage of Real-World DataSurvey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data.
Latest:
The New Era of HCP Engagement: What’s Next on the Path to Digital ExcellenceCompanies now have a unique opportunity to rethink their customer engagement strategy and find new techniques to serve healthcare professionals more effectively.
Latest:
Strategic Decision-Making in Early-Stage Drug Development and Lifecycle Management to Maximize a Drug’s Lifetime ValuePresenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.
Latest:
A Dogged DevotionSaving and transforming as many patients’ lives as possible has been the driving force behind Beth Seidenberg’s audacious career, where she has excelled as a doctor, researcher, and venture capitalist.
Latest:
Partnering to Respond to a Possible Nuclear ThreatRecent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.
Latest:
Unlocked Potential — ‘Keying’ in On New-Era EngagementHow adoption of the key account management (KAM) model can help drive pharma’s agility in reaching and influencing a more diverse set of healthcare customers and decision-makers.
Latest:
Patients Are Ready for a Digital Future, Here’s Pharma’s Path Toward the Next Growth HorizonRecent advances from COVID-19 vaccine development put pharma in place to further grow relationship with patients.
Latest:
Pharma's ESG Equation: Materiality and Strategy are KeyLife sciences executives who are confronted by too many choices in launching their environmental, social, and governance programs can leverage these two foundational tools to hone in on the set of issues, actions, and disclosures they should prioritize to create value.
Latest:
Project Orbis: Implications for Access and Pricing in the UKPost-Brexit, the UK’s MHRA is looking to join Project Orbis, a global program to speed up patient access to innovative cancer treatments. This article looks at the implications of Project Orbis for commercialization in the UK and the key considerations for industry in considering the project as a pathway.
Latest:
Industry Game Changer: RWE Impacts on Drug DevelopmentCOVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.
Latest:
The Power of Virtual Patient Simulation in CMEVPS access for clinicians is critical in today’s healthcare climate
Latest:
Assessing IDMP MaturityHow pharma firms assess their readiness for IDMP (Identification of Medicinal Products) is important for meeting compliance requirements and ensuring they are prepared for the digital product information management future, writes Adnan Jamil.
Latest:
Bringing Data to Life: How Tech-Savvy Life Sciences Companies Can Better Serve the Healthcare SectorGoing beyond traditional market segmentation to understand the technological and data analytics capacity of target customers.
Latest:
Plan Ahead: Mastering Your AI Budget for 2025 SuccessGenerative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.
